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Abstract 
Background  
Chronic pain is a common, disabling, and costly comorbidity, particularly in people living with 
HIV (PLWH). We developed and pilot tested a pain self-management intervention for chronic 
pain tailored to PLWH called Skills TO Manage Pain (STOMP).  
 
Objectives 
Given the additional resources needed to deliver STOMP in HIV clinical settings, an important 
objective of the pilot study was to  assess not only STOMP’s preliminary efficacy, but also its 
cost-effectiveness. 
 
Research Design and Subjects 
The present study draws from a 44-participant, 2 arm randomized pilot trial of the STOMP 
intervention vs. usual care among PLWH and at least moderate chronic pain (Clinicaltrials.gov: 
NCT02824562). Cost-effectiveness is presented as the incremental cost-effectiveness ratio 
(ICER). Costs were considered from the clinic perspective over a one-year time horizon using 
real costs from the pilot trial. We conservatively assumed no costs savings. The Standard 
Gamble (SG) method was used to directly measure utilities. 
 
Results 
Thirty-six participants met inclusion criteria for the present analyses. Mean age was 52 years, 
61% were female, and 86% were black.  The total cost of STOMP was $483.83 per person. 
Using the SG method, the change in QALYs was 0.15, corresponding to an ICER of $3,225. 
 
Conclusions 
STOMP’s cost/QALY is substantially lower than the $50,000-100,000/QALY benchmark often 
used to indicate cost-effectiveness. Although based on a pilot trial and therefore preliminary, our 
findings are promising and suggest the importance of cost analyses in future STOMP trials. 
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Introduction  
Chronic pain is a common, disabling, and costly comorbidity.1 Due to the serious risks and 
limited benefits of medications to treat chronic pain, the 2016 U.S. Department of Health and 
Human Services National Pain Strategy called for the development of non-pharmacologic 
interventions to improve chronic pain sufferers’ quality of life, especially in populations most 
affected.2 These include Pain Self-Management (PSM) interventions, which are behavioral 
interventions tailored to the needs of a specific target population. PSM interventions are 
designed to improve quality of life by enhancing self-management skills such as thinking 
differently about pain and engagement in adaptive pain coping strategies.3-5  
Chronic pain is of particular importance in people living with HIV (PLWH). The prevalence of 
chronic pain is high in PLWH (39-85%, as compared to 15% in the general population6-8) and 
chronic pain is associated with important outcomes such as suboptimal retention in HIV primary 
care.8 However, there is a relative paucity of interventions developed or tested in this 
population9. To that end, we developed a PSM intervention for chronic pain tailored to PLWH 
called Skills TO Manage Pain (STOMP). Extensive qualitative intervention development work 
highlighted the importance of incorporating three novel components in this population: 1) Group 
sessions: Group sessions are intended to enhance social support in this particularly isolated 
group of patients. 2) Peer leaders: The group sessions are peer co-led to allow participants to 
learn through observing peers who are successful pain self-managers; and 3) Learning self-
management skills from an expert:  The group sessions accompany a menu of one-on-one skill-
building sessions that include the topics of pain education, physical activity to improve pain, 
thinking differently about your pain, sleep and pain, and relaxation, among other topics. The 
peer co-led group sessions and one-on-one sessions alternate over 12 weeks.10 A recent pilot 
trial suggests that STOMP is feasible and acceptable to participants  
Given the additional resources needed to deliver this intervention in HIV clinical settings, 
research to advance this line of work requires investigation of not only STOMP’s efficacy, but 
also its cost-effectiveness. There is some evidence from the chronic low back pain literature to 
suggest that non-pharmacologic approaches (including behavioral interventions) may be cost 
effective.11-13 However, the cost-effectiveness of relatively labor intensive interventions such as 
PSM has not been established. Furthermore, the recent US Department of Health and Human 
Services’ National Pain Strategy identified developing cost-effective approaches to pain 
management as a key next step.2 Thus, an important aim of the pilot study was to assess 
STOMP’s preliminary cost-effectiveness. One way to approach effectiveness is to assess the 
change in utility of the health state in question. Utility is the value one assigns to a given health 
state, in this case chronic pain. To our knowledge, no study to date has directly measured 
chronic pain utilities in PLWH. 
This analysis uses costs from the pilot trial and direct measures to assess chronic pain utilities. 
Exploratory analyses of STOMP’s impact on chronic pain utilities were conducted. We also 
placed these results in context by investigating the association of these utility values with other 
commonly-used measures of pain and quality of life.  
 
Methods 
Participants 
This study draws from a 44-participant, 2 arm randomized pilot trial of STOMP intervention vs. 
usual care (Clinicaltrials.gov: NCT02824562). This pilot trial recruited from the University 
Alabama Birmingham (UAB) 1917 HIV Clinic Cohort, one of eight sites of the national Center for 
AIDS Research Network of Integrated Clinical Systems (CNICS) cohort14. Participants were 
surveyed at baseline and within one month of pilot trial completion or within one month after the 
last group session for the control participants. Analyses are limited to individuals who met trial 
inclusion criteria (≥ moderate pain for ≥ three months [pain of at least moderate severity for at 
least months on the Brief Chronic Pain Questionnaire15 and an average score of ≥4 on the 
question PEG, which measures pain severity and pain-related impairment in enjoyment of life 
and general activities16], no upcoming surgical procedures, ability to attend intervention 
sessions) and who completed baseline and follow-up outcome assessments. This study was 
approved by the UAB Institutional Review Board. 
Demographic information was obtained from the CNICS database. Study-specific baseline and 
outcome assessments included the SF-12, a population normed measure of health status.17 The 
SF-6D score, a preference-based single index measure developed to calculate health utilities 
using general population values, was derived from the SF-12 data.18 Assessments also included 
the 11-question Brief Pain Inventory (BPI)17, from which the BPI-total score was calculated by 
averaging all responses on a scale of 0-10, which is a measure of pain and pain-related 
functional impairment, the PHQ-8, a measure of depressive symptoms19 (score ≥ 10 indicates 
moderate or greater symptoms), and direct utility measures as described below. 
Utilities 
This study used the Standard Gamble (SG) to measure utility. Participants were asked to 
imagine a hypothetical pill that would cure them of chronic pain for the rest of their life, but might 
cause an immediately fatal allergic reaction. They were asked to report the maximum chance of 
death between 0-100% that they would be willing to accept to take the pill.  
Chronic pain utility is the chance of fatal reaction offered by the participant subtracted from 100, 
given as decimal. Thus, if a respondent said he or she would accept a 100% chance of death, 
the utility associated with chronic pain would be zero (i.e. the same utility as death); if no chance 
of death were acceptable, the health state would be rated as one. Utilities averages were 
calculated for both arms at baseline and after the intervention. Post-intervention utilities were 
compared using a t-Test. 
 
Preliminary cost-effectiveness 
Cost-effectiveness is commonly summarized by the Incremental Cost-Effectiveness Ratio 
(ICER). For an intervention such as STOMP, the ICER is calculated as the change in cost (cost 
spent on the intervention minus costs saved), divided by the change in quality adjusted life 
years (QALYs). Participants were not followed after the pilot concluded, so cost savings, if any, 
could not be calculated, and we conservatively assumed there were none. Costs were 
calculated as average fixed costs plus variable costs per person. Costs were considered from a 
clinic perspective, since it is likely a clinic director who would decide whether to implement a 
program like STOMP. Behavioral interventions are often evaluated over at least one year. 
Therefore, we chose a one year time horizon; we then tested the effect of varying the duration 
of benefit in sensitivity analyses described below. We assumed a clinic would need to train one 
staff person for all interventionist functions and two peers to provide adequate “coverage.” 
Based on lessons learned from our pilot, one staff and one peer interventionist worked with a 
group of 10 participants over 16 weeks, equating to 40 study participants annually. Fixed costs 
consist of up-front training, and variable costs include staff costs to conduct one-on-one and 
group sessions, reminder calls, and other participant incidentals (snacks, travel vouchers, and 
manuals).  Change in QALYS was calculated using the SG utility x time. The ICER was then 
calculated as the costs of the intervention divided by the difference in QALYs between the 
STOMP intervention and control arms. The ICER was evaluated at a willingness to pay (WTP) 
of $50,000 per QALY. Cost-effectiveness analyses were conducted using TreeAge Pro Version 
2015 (TreeAge Software, Inc., Williamstown, MA). 
Sensitivity Analysis 
One-way sensitivity analyses were conducted to assess the influence of each of the cost 
effectiveness analysis model parameters (costs and QALYs for the STOMP arm, and QALYs for 
the control arm). Probabilistic sensitivity analyses were conducted using Monte Carlo 
simulations, drawing from random distributions of cost and QALY estimates. Results from the 
simulations were then use to construct a CE Acceptability Curve, plotting the probability the 
intervention would be considered cost-effective at a willingness to pay from 0 to $100,000 per 
QALY. 
Associations of utility measures with outcomes 
Spearman correlation was used to investigate the relationship between each participant’s SG 
utility value and other outcomes: 1) the Brief Pain Inventory-Total Score and 2) the SF-6D.  
 
Results 
Thirty-six participants met inclusion criteria for the present analyses. Table 1 summarizes their 
baseline characteristics by group. Overall, mean age was 52 years (SD 6.3), 22 (61%) were 
female, and 31 (86%) were black.  All patients reported being prescribed anti-retroviral therapy 
for their HIV disease, and one had a detectable viral load. Pain locations included hands and 
feet (18), lower back (27), knee (21), and hip (15). Mean BPI was 7.4 (SD 2), and mean SF-6D 
was 0.6 (SD 0.1). Mean PHQ-8 score was 9.1 (SD 5.5). 
Utilities  
Utilities are summarized in Table 2. The baseline utilities using SG were 0.785 for the STOMP 
arm compared with 0.685 for controls (p = 0.387).  Post-intervention utilities were 0.878 for the 
STOMP arm and 0.629 for controls (p = 0.022).   
Cost-effectiveness  
Cost calculations are summarized in Table 3.The total cost of STOMP = fixed costs + variable 
costs = $204.20 + 279.63 = $483.83 per person. The change in QALYs was 0.15 so ICER 
would be $3,225 per QALY gained. 
 
One-way sensitivity analyses found that the baseline effects differed only for the estimate of 
QALYs for the STOMP intervention arm. As long as the intervention prevented deterioration in 
QALYs by less than 0.02, the intervention would be considered cost-effective (at Willingness to 
Pay (WTP) > $50,000). The probabilistic sensitivity analysis (Figure 1) found that if WTP per 
QALY were $5,000 per QALY there would be a greater than 50% probability that the 
intervention would be considered cost-effective; the probability rises to 80% at $12,000 per 
QALY. The Cost Effectiveness Acceptability Curve is asymptotic at 90% for a WTP > $36,000, 
indicating that there is a 10% chance that the estimated QALYs for the STOMP arm would be 
less than those for the control arm. 
 
Associations of utility measures with outcomes 
No correlations between SG utilities and the BPI or SF-6D before or after the intervention were 
significant. 
 
Discussion 
To our knowledge, this is the first cost-effectiveness evaluation of a chronic pain intervention for 
PLWH, and also the first direct measurement of chronic pain utilities among people living with 
both HIV and chronic pain. Although based on a pilot trial, STOMP’s cost/QALY is far lower than 
the commonly referenced $50,000-100,000/QALY benchmark.20  Also, prior to STOMP, 
participants reported SG utilities comparable to those reported in other studies of chronic pain 
conditions21 such as low back pain22 and osteoarthritis23, and other painful conditions such as 
rheumatoid arthritis.24  These findings underscore the profound negative impact of pain on 
contemporary HIV-infected patients’ quality of life, and the need for efficacious, cost-effective 
interventions. 
Our findings also underscored STOMP’s potential impact on participant quality of life. 
Differences in utilities between groups after the intervention were sizeable and statistically 
significant. This suggests that after receiving the STOMP intervention, participants were willing 
to accept a smaller probability of death to receive an efficacious but potentially dangerous 
treatment, compared to their pre-intervention assessment. In other words, in regard to their 
chronic pain, participants placed a greater value on their lives after STOMP than before. This 
may have real-world implications. For example, opioids are widely prescribed for chronic pain, 
and  are associated with serious risks, including death.25.26 STOMP may cause participants to 
be less willing to accept these risks, as participants realize they can control their pain with the 
skills they have learned.  
Both before and after the STOMP intervention, there was no correlation between SG utilities 
and the BPI or SF-6D. This reflects the difference between utility measurement and the 
constructs measured by these instruments. For example, BPI reflects pain and pain-related 
functional impairment, while the SG more broadly measures participants’ overall impressions 
and feelings about having chronic pain. Utility measures are likely to encompass intangibles 
beyond the direct disutility of pain, such as its effects on emotional and physical well-being, as 
well as a person’s resilience or ability to cope with pain. To the extent that interventions seek to 
alleviate suffering rather than resolve pain, however, SG may be more relevant. Additionally, 
lack of correlation between direct utility measurements and the SF-6D suggests that the SF-6D 
may need to be renormed for PLWH who have chronic pain. 
This study has limitations. This was a small pilot study and our findings are therefore 
preliminary. Utilities were measured on trial participants, who may not represent the general 
population of PLWH with chronic pain. Furthermore, this pilot study did not follow participants 
long enough to provide an estimate of the duration of beneficial effects. It is also possible that 
STOMP could have an impact on other health care utilization, potentially resulting in cost 
savings. These savings would be, however, unlikely to affect the costs to the clinic, which was 
the perspective taken in this study. A larger study could consider a broader perspective. 
Although the sensitivity analyses indicate that STOMP is likely to be cost-effective, there 
remains considerable uncertainty as to the precise value in costs per QALY. Finally, although 
randomization occurred at the patient level. We did not account for potential clustering within 
groups or interventionists.  
 
Conclusion 
In sum, this study contributes to the literature on cost-effectiveness of interventions to address 
chronic pain in PLWH. The next step in this line of research is to conduct a full-scale efficacy 
trial of the intervention and a more comprehensive cost-effectiveness evaluation. If the 
intervention demonstrates efficacy, such an evaluation will be central to understanding the 
intervention’s scalability and broader public health impact.   
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